Preparing for biocompatibility testing for medical devices requires a structured, regulatory-driven approach. In 2026, authorities such as the U.S. FDA and EU MDR regulators expect manufacturers to follow a risk-based framework aligned with ISO 10993 and ISO 14971 standards.
Without proper preparation, companies often face FDA deficiency letters, extended review timelines, and additional testing costs.
Materials Metric works with medical device manufacturers globally to develop regulatory-ready biological evaluation strategies that accelerate approvals and ensure full compliance.
This step-by-step checklist outlines how to properly prepare for biocompatibility testing while reducing regulatory risk.
Step 1: Determine Device Classification and Body Contact
Before initiating biocompatibility testing for medical devices, manufacturers must clearly define:
• Device classification (Class I, II, III)
• Nature of body contact (skin, mucosal, blood, tissue, implant)
• Duration of exposure (limited, prolonged, permanent)
These factors determine which ISO 10993 testing endpoints are required.
For example:
Surface contact devices typically require cytotoxicity and irritation testing.
Implantable medical devices may require systemic toxicity, genotoxicity, and implantation studies.
Materials Metric assists manufacturers in mapping device characteristics to regulatory testing matrices to avoid unnecessary or missing test endpoints.
Step 2: Develop a Biological Evaluation Plan (BEP)
Under ISO 10993-1, regulators now expect a documented Biological Evaluation Plan.
The BEP should include:
• Device material composition
• Intended clinical use
• Exposure duration and contact type
• Risk assessment summary
• Proposed biological endpoints
• Justification for omitted tests
The FDA specifically reviews BEPs in 510(k) submissions to confirm a risk-based approach.
Materials Metric supports clients in drafting compliant Biological Evaluation Plans aligned with FDA biocompatibility guidance 2026.
Ready to streamline your Biocompatibility Testing for Medical Devices?
Partner with Materials Metric for a fully compliant, risk-based biological evaluation strategy aligned with ISO 10993, FDA, and EU MDR requirements. Our experts help you reduce regulatory delays and accelerate product approvals. Contact Materials Metric today to start your regulatory-ready testing program.
Step 3: Conduct Chemical Characterization (ISO 10993-18)
Modern regulatory frameworks emphasize chemical characterization before animal testing.
Under ISO 10993-18, manufacturers must:
• Identify extractable compounds
• Quantify leachable substances
• Assess patient exposure thresholds
• Conduct toxicological risk assessment under ISO 10993-17
Analytical techniques commonly used include:
• Gas Chromatography–Mass Spectrometry (GC-MS)
• Liquid Chromatography–Mass Spectrometry (LC-MS)
• Inductively Coupled Plasma–Mass Spectrometry (ICP-MS)
Materials Metric provides comprehensive extractables and leachables testing services to support regulatory submissions and reduce the need for excessive in vivo studies.
Step 4: Integrate Risk Management Under ISO 14971
Biocompatibility testing decisions must align with medical device risk management documentation.
Manufacturers should:
• Identify biological hazards
• Estimate severity and probability
• Document mitigation strategies
• Evaluate residual risk
Regulators increasingly verify that testing strategies correspond directly to documented risk assessments.
Materials Metric ensures that biological evaluation aligns with ISO 14971 risk management files for seamless regulatory review.
Step 5: Select Required ISO 10993 Test Endpoints
Depending on device type, required testing may include:
ISO 10993-5 Cytotoxicity Testing
ISO 10993-10 Irritation and Sensitization
ISO 10993-11 Systemic Toxicity
ISO 10993-4 Hemocompatibility
ISO 10993-3 Genotoxicity
ISO 10993-6 Implantation Studies
A strategic testing matrix prevents over-testing while maintaining compliance.
Materials Metric customizes testing programs based on device risk profile and regulatory pathway.
Step 6: Choose a GLP-Compliant Testing Laboratory
Regulatory submissions require accurate, traceable, and GLP-aligned data.
Selecting a qualified laboratory ensures:
• Validated testing protocols
• Regulatory-ready reporting
• Accurate toxicological interpretation
• Reduced FDA review queries
Materials Metric operates under internationally recognized laboratory standards, delivering high-quality data suitable for global submissions.
Step 7: Prepare the Biological Evaluation Report (BER)
After completing all required tests, manufacturers must compile a Biological Evaluation Report.
The BER includes:
• Summary of testing results
• Chemical characterization findings
• Toxicological risk assessment conclusions
• Justification for omitted endpoints
• Final biological safety determination
Materials Metric provides structured BER documentation designed to meet FDA, EU MDR, and global regulatory expectations.
Common Mistakes in Biocompatibility Preparation
• Skipping chemical characterization
• Failing to justify omitted tests
• Ignoring extractables and leachables requirements
• Incomplete risk management documentation
• Using non-compliant laboratories
A proactive regulatory strategy reduces approval delays and additional testing requests.
Estimated Timeline for Biocompatibility Testing in 2026
Cytotoxicity testing: 2–4 weeks
Sensitization and irritation: 4–8 weeks
Full biological evaluation program: 3–6 months
Early planning with Materials Metric can significantly shorten overall regulatory timelines.
Planning your Biocompatibility Testing for Medical Devices in 2026?
Let Materials Metric develop a customized Biological Evaluation Plan, chemical characterization strategy, and complete regulatory documentation tailored to your device classification. Schedule a consultation with our regulatory specialists to ensure your submission is approval-ready.
Conclusion
Proper preparation for biocompatibility testing for medical devices is critical to achieving regulatory approval efficiently. A structured approach aligned with ISO 10993, ISO 14971, FDA guidance, and EU MDR expectations minimizes risk and accelerates market entry.
Materials Metric provides comprehensive, regulatory-ready biocompatibility testing services, including chemical characterization, toxicological risk assessment, and complete documentation support for global medical device manufacturers.
Partnering with Materials Metric ensures compliance, patient safety, and successful regulatory outcomes.
Frequently Asked Questions
What is the first step in biocompatibility testing for medical devices?
The first step is determining device classification, body contact type, and exposure duration under ISO 10993-1.
Is a Biological Evaluation Plan mandatory for FDA submissions?
Yes. The FDA expects a documented Biological Evaluation Plan outlining required endpoints and risk-based justifications.
How long does biocompatibility testing take?
Basic testing can take several weeks, while complete biological evaluation programs may take several months depending on device risk classification.
Do Class II medical devices require biocompatibility testing?
Most Class II devices require biological evaluation data as part of FDA 510(k) clearance.
Why is chemical characterization important before in vivo testing?
Chemical characterization identifies potential toxic compounds early, reducing unnecessary animal testing and supporting regulatory compliance.
People Also Search For: biocompatibility testing for medical devices, ISO 10993 testing requirements, FDA biocompatibility guidance 2026, medical device regulatory compliance, biological evaluation of medical devices, 510k biocompatibility testing, EU MDR biocompatibility requirements, medical device safety testing services, toxicological risk assessment ISO 10993, Class II medical device testing requirements, ISO 10993-1 biological evaluation plan, ISO 10993-5 cytotoxicity testing, ISO 10993-10 irritation and sensitization, ISO 10993-11 systemic toxicity testing, ISO 10993-18 chemical characterization, extractables and leachables testing, FDA medical device approval process, GLP certified laboratory testing, ISO 14971 risk management medical devices, implantable device biocompatibility testing
